Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fumitake Hata

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
JCI Insight|June 29, 2021
Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissueTomomi Hirama, Serina Tokita, Munehide Nakatsugawa, et al.
Surgery Today|May 10, 2002
Transanal repair of rectourethral fistula after a radical retropubic prostatectomy: report of a caseFumitake Hata, Takahiro Yasoshima, Shingo Kitagawa, et al.
Surgery Today|July 11, 2002
Malignant melanoma of the anorectum: report of four casesRika Fukui, Fumitake Hata, Takahiro Yasoshima, et al.
Cancer Immunology Research|January 27, 2018
The Antigen ASB4 on Cancer Stem Cells Serves as a Target for CTL Immunotherapy of Colorectal CancerSho Miyamoto, Vitaly Kochin, Takayuki Kanaseki, et al.
Journal of Translational Medicine|May 13, 2008
Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancerTetsuhiro Tsuruma, Yuji Iwayama, Tosei Ohmura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2005
A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteinsSatomi Idenoue, Yoshihiko Hirohashi, Toshihiko Torigoe, et al.
Journal of Translational Medicine|June 15, 2004
Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancerTetsuhiro Tsuruma, Fumitake Hata, Toshihiko Torigoe, et al.
The Japanese Journal of Antibiotics|July 7, 2005
[Bacteria isolated from surgical infections and its susceptibilities to antimicrobial agents--special references to bacteria isolated between April 2003 and March 2004]Nagao Shinagawa, Koichi Hirata, Tadashi Katsuramaki, et al.
The Japanese Journal of Antibiotics|January 1, 2015
[Bacteria isolated from surgical infections and its susceptibilities to antimicrobial agents--special references to bacteria isolated between April 2010 and March 2011]Nagao Shinagawa, Masaaki Taniguchi, Koichi Hirata, et al.
The Japanese Journal of Antibiotics|March 24, 2015
[Bacteria isolated from surgical infections and its susceptibilities to antimicrobial agents - Special references to bacteria isolated between April 2011 and March 2012]Nagao Shinagawa, Masaaki Taniguchi, Koichi Hirata, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
JCI Insight|June 29, 2021
Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissueTomomi Hirama, Serina Tokita, Munehide Nakatsugawa, et al.
Surgery Today|May 10, 2002
Transanal repair of rectourethral fistula after a radical retropubic prostatectomy: report of a caseFumitake Hata, Takahiro Yasoshima, Shingo Kitagawa, et al.
Surgery Today|July 11, 2002
Malignant melanoma of the anorectum: report of four casesRika Fukui, Fumitake Hata, Takahiro Yasoshima, et al.
Cancer Immunology Research|January 27, 2018
The Antigen ASB4 on Cancer Stem Cells Serves as a Target for CTL Immunotherapy of Colorectal CancerSho Miyamoto, Vitaly Kochin, Takayuki Kanaseki, et al.
Journal of Translational Medicine|May 13, 2008
Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancerTetsuhiro Tsuruma, Yuji Iwayama, Tosei Ohmura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2005
A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteinsSatomi Idenoue, Yoshihiko Hirohashi, Toshihiko Torigoe, et al.
Journal of Translational Medicine|June 15, 2004
Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancerTetsuhiro Tsuruma, Fumitake Hata, Toshihiko Torigoe, et al.
The Japanese Journal of Antibiotics|July 7, 2005
[Bacteria isolated from surgical infections and its susceptibilities to antimicrobial agents--special references to bacteria isolated between April 2003 and March 2004]Nagao Shinagawa, Koichi Hirata, Tadashi Katsuramaki, et al.
The Japanese Journal of Antibiotics|January 1, 2015
[Bacteria isolated from surgical infections and its susceptibilities to antimicrobial agents--special references to bacteria isolated between April 2010 and March 2011]Nagao Shinagawa, Masaaki Taniguchi, Koichi Hirata, et al.
The Japanese Journal of Antibiotics|March 24, 2015
[Bacteria isolated from surgical infections and its susceptibilities to antimicrobial agents - Special references to bacteria isolated between April 2011 and March 2012]Nagao Shinagawa, Masaaki Taniguchi, Koichi Hirata, et al.
Pageof 6